Stock Research: Sanofi

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Sanofi

ENXTPA:SAN FR0000120578
77
  • Value
    60
  • Growth
    29
  • Safety
    Safety
    97
  • Combined
    75
  • Sentiment
    63
  • 360° View
    360° View
    77
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Sanofi SA is a French healthcare company focused on the research, development, and marketing of therapeutic solutions. It operates in the Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines industries. Sanofi operates globally, with a focus on research and development of therapeutic solutions. In the last fiscal year, the company had a market cap of $118754 million, profits of $32178 million, and revenue of $45849 million, with 84587 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 77 (better than 77% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock Sanofi are very positive. The 360° View is based on consolidating four consolidated indicators, with half of the indicators below and half above average for Sanofi. The consolidated Value Rank has an attractive rank of 97, which means that the share price of Sanofi is on the lower side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 97% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 60. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 63. But the consolidated Growth Rank has a low rank of 29, which means that the company is below average in terms of growth and momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. 71 of its competitors have better growth. ...read more

more
Index
EURO STOXX 50
CAC 40
CAC All
SBF 120
Dividends Europe
Diversity Europe
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
97 98 99 96
Growth
29 60 51 61
Safety
Safety
60 76 56 27
Sentiment
63 92 44 40
360° View
360° View
77 98 82 60
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
77 76 45 55
Opinions Change
19 49 47 26
Pro Holdings
n/a 94 86 84
Market Pulse
49 50 19 23
Sentiment
63 92 44 40
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
97 98 99 96
Growth
29 60 51 61
Safety Safety
60 76 56 27
Combined
75 95 90 65
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
85 86 86 87
Price vs. Earnings (P/E)
62 50 61 71
Price vs. Book (P/B)
80 79 88 78
Dividend Yield
96 94 92 92
Value
97 98 99 96
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
39 61 39 43
Profit Growth
39 50 46 45
Capital Growth
59 55 67 66
Stock Returns
31 77 48 66
Growth
29 60 51 61
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
68 68 56 47
Refinancing
39 42 43 6
Liquidity
54 73 63 61
Safety Safety
60 76 56 27

Similar Stocks

Discover high‑ranked alternatives to Sanofi and broaden your portfolio horizons.

Rubis

ENXTPA:RUI
Country: France
Industry: Gas Utilities
Size: Medium
Full Stock Analysis

Savencia

ENXTPA:SAVE
Country: France
Industry: Packaged Foods & Meats
Size: Medium
Full Stock Analysis

Societe Generale

ENXTPA:GLE
Country: France
Industry: Diversified Banks
Size: Medium
Full Stock Analysis

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.

BUSE:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.